G6PC1 and glioblastoma: In several malignancies originating from non-gluconeogenic organs, such as glioblastoma, ovarian cancer, gastric cancer, and cervical carcinoma, elevated G6PC1 expression has been detected and is associated with enhanced tumor aggressiveness and metastatic potential (10, 57–59).